EHA 2014 Conference Review - Focus on Multiple Myeloma

In this Issue:

Continuous vs. fixed duration therapy in newly diagnosed MM
SAR650984, a CD38 mAb, in relapsed/refractory MM
Early autologous SCT improves survival in newly diagnosed MM
Effect of other cytogenetic abnormalities in high-risk MM
Revised ISS for MM
Panobinostat plus bortezomib and dexamethasone in relapsed/ refractory MM
Lenalidomide + low-dose dexamethasone vs. MPT in newly diagnosed MM
Updated trial data of induction VMP vs. VTP in MM
Cytogenetics and pomalidomide plus low-dose dexamethasone in relapsed/refractory MM
Frontline SC bortezomib-based induction and consolidation in SCT-eligible MM

Please login below to download this issue (PDF)

Subscribe